Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average recommendation of “Moderate Buy” by the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $52.4444.

Several equities analysts have recently issued reports on STRO shares. Citizens Jmp boosted their price objective on Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a research report on Thursday, April 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Friday, May 8th. Wells Fargo & Company upgraded Sutro Biopharma from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $8.00 to $27.00 in a research report on Tuesday, March 24th. Wall Street Zen cut Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Finally, Lifesci Capital raised Sutro Biopharma to a “strong-buy” rating in a report on Friday, May 1st.

Sutro Biopharma Stock Down 0.4%

STRO stock opened at $33.20 on Friday. The stock has a market cap of $550.12 million, a PE ratio of -3.01 and a beta of 1.54. The firm’s 50-day simple moving average is $31.82 and its 200 day simple moving average is $22.80. Sutro Biopharma has a fifty-two week low of $6.74 and a fifty-two week high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The business had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million. Equities analysts forecast that Sutro Biopharma will post -9 EPS for the current fiscal year.

Hedge Funds Weigh In On Sutro Biopharma

Several large investors have recently bought and sold shares of the stock. Bridgeway Capital Management LLC raised its position in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares in the last quarter. Invesco Ltd. increased its stake in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares during the period. Cerity Partners LLC raised its holdings in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after purchasing an additional 66,372 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Sutro Biopharma during the second quarter worth approximately $82,000. Finally, State of Tennessee Department of Treasury acquired a new stake in Sutro Biopharma in the fourth quarter worth approximately $86,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.